Disease & disorder
infiltrating bladder urothelial carcinoma
MONDO:0003890
An invasive transitional cell carcinoma that arises from the urinary bladder urothelium.
Research intelligence
Directly mapped studies only · unique clinical trialsCurrent registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.
Medications under investigation
Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.
Loading mapped interventions…
MONDO disease family
Loading verified ontology relationships…
Recruiting studies by city
Loading research-site locations…
Trial status
Loading…
Trial phase
Loading…
Study start year
Loading…
Investigated drug interventions
Loading…
Clinical trials
2 shownTesting the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsNCT03866382 · 2019-05-13
RECRUITINGsEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney CancerNCT02767921 · 2016-08-02
TERMINATEDDrugs being studied
Research locations
Los AngelesCalifornia, United States2AllentownPennsylvania, United States1Ann ArborMichigan, United States1AtlantaGeorgia, United States1AventuraFlorida, United States1BaltimoreMaryland, United States1Baton RougeLouisiana, United States1BellevueWashington, United States1BethesdaMaryland, United States1BillingsMontana, United States1BirminghamAlabama, United States1BoiseIdaho, United States1
Leading sponsors
Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.